AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Heart Failure in Women: Epidemiological and Prognostic Insights

Recruitingn/aAges 18 Years - anyFemaleCarolina Ortiz Cortes
💬

In plain words

What the trial is, and whether it could suit you

Heart failure (HF) is a leading cause of hospital admission in older adults and women account for more than half of these admissions, yet they remain under-represented in prospective HF cohorts. Risk factors specific to women, such as complications of pregnancy and the timing of menopause, are seldom recorded in HF registries, and treatment is usually described by drug class rather than by the dose actually achieved. HER-HF is a national, prospective, multicenter observational cohort study that enrolls women aged 18 years or older admitted to hospital for a first episode of HF, irrespective of left ventricular ejection fraction, at 24 Spanish hospitals with a dedicated heart failure unit. Recruitment is consecutive and all-comers. Participants are enrolled at discharge from the index admission or at the first heart failure unit visit within 15 days, and all baseline data refer to the in

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Women aged 18 years or older. * Hospital admission with a first episode of heart failure confirmed by the treating team according to current clinical practice guidelines, irrespective of left ventricular ejection fraction. * Written informed consent given by the participant after verbal and written information. Exclusion Criteria: * Total functional dependence, defined as a Barthel index score of 20 or less (0-100 version). * Moderate-to-severe cognitive impairment, defined as 5 or more errors on the Pfeiffer questionnaire, adjusted for educational attainment. * Severe frailty, defined as a Clinical Frailty Scale score of 6 or more. * Terminal illness unrelated to heart failure with an expected survival of less than 6 months according to clinical judgment. * Inability to complete clinical follow-up or subsequent contact (for example, no contact details available, or transfer to a center outside the network). * Any previous diagnosis of heart failure.
💊

What it tests

  • Not listed
📍

Where

24 sites
Complexo Hospitalario Universitario A Coruna
A Coruña, Spain
Hospital Clinico Universitario de Santiago de Compostela
Santiago de Compostela, Spain
Hospital Universitario de Badajoz
Badajoz, Spain
Hospital Universitario de Burgos
Burgos, Spain
Hospital Universitario de Caceres
Cáceres, Spain
Hospital Universitario Puerta del Mar
Cadiz, Spain
Hospital Universitario Donostia
Donostia / San Sebastian, Spain
Hospital Universitari de Girona Doctor Josep Trueta
Girona, Spain

…and 16 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy